New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx
- PMID: 39733164
- PMCID: PMC11682409
- DOI: 10.1038/s41598-024-82983-7
New-onset cardiovascular diseases post SARS-CoV-2 infection in an urban population in the Bronx
Abstract
This study investigated the incidence of new-onset cardiovascular disorders up to 3.5 years post SARS-CoV-2 infection for 56,400 individuals with COVID-19 and 1,093,904 contemporary controls without COVID-19 in the Montefiore Health System (03/11/2020 to 07/01/2023). Outcomes were new incidence of major adverse cardiovascular event (MACE), arrhythmias, inflammatory heart disease, thrombosis, cerebrovascular disorders, ischemic heart disease and other cardiac disorders between 30 days and (up to) 3.5 years post index date. Results were also compared with a pre-pandemic cohort over similar observation duration (N = 64,541). Cumulative incidence and hazard ratios adjusted for competitive risks were analyzed. Compared to contemporary controls, hospitalized COVID-19 patients had significantly higher risk of developing MACE (aHR = 2.29, 95% confidence interval [2.27, 2.31], p < 0.001), arrhythmias (aHR = 2.54[2.50, 2.58], p < 0.001), inflammatory heart disease (aHR = 5.34[4.79, 5.96], p < 0.001), cerebrovascular (aHR = 2.05[2.00, 2.11], p < 0.001), other cardiac disorders (aHR = 2.31[2.26, 2.35], p < 0.001), thrombosis (aHR = 4.25[4.15, 4.36], p < 0.001), and ischemic heart disease (aHR = 1.89[1.86, 1.92], p < 0.001). Non-hospitalized COVID-19 patients had slightly higher risk of developing MACE (aHR = 1.04[1.03, 1.06], p < 0.001), arrhythmias (aHR = 1.10[1.08, 1.12], p < 0.001), inflammatory heart disease (aHR = 2.29 [2.03, 2.59], p < 0.001), cerebrovascular (aHR = 1.11[1.07, 1.15], p < 0.001), and ischemic heart disease (aHR = 1.10[1.08, 1.13], p < 0.001). Race and ethnicity were mostly not associated with increased risks (p > 0.05). aHRs with contemporary controls as a reference were similar to those with pre-pandemic cohort as a reference. We concluded that new incident cardiovascular disorders in COVID-19 patients, especially those hospitalized for COVID-19, were higher than those in controls. Identifying risk factors for developing new-onset cardiovascular disorders may draw clinical attention for the need for careful follow-up in at-risk individuals.
Keywords: heart attack; long COVID-19; myocarditis; post-acute sequelae of COVID-19 (PASC); stroke.
© 2024. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests. Consent to participate: Informed Consent was waived as this retrospective study was approved by the Einstein-Montefiore Institutional Review Board (#2021–13658) with an exemption for informed consent and a HIPAA waiver.
Figures
Similar articles
-
Long term outcomes of patients with chronic kidney disease after COVID-19 in an urban population in the Bronx.Sci Rep. 2025 Feb 19;15(1):6119. doi: 10.1038/s41598-025-90153-6. Sci Rep. 2025. PMID: 39972044 Free PMC article.
-
Long-term outcomes of patients with a pre-existing neurological condition after SARS-CoV-2 infection.J Neurol Sci. 2025 Jun 15;473:123477. doi: 10.1016/j.jns.2025.123477. Epub 2025 Apr 2. J Neurol Sci. 2025. PMID: 40328113
-
SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population.Mult Scler Relat Disord. 2024 Jun;86:105613. doi: 10.1016/j.msard.2024.105613. Epub 2024 Apr 8. Mult Scler Relat Disord. 2024. PMID: 38608516
-
Patients With Type 2 Diabetes Are at Greater Risk of Developing New Hypertension and Chronic Kidney Disease Following COVID-19.J Diabetes Res. 2025 Jun 4;2025:8816198. doi: 10.1155/jdr/8816198. eCollection 2025. J Diabetes Res. 2025. PMID: 40503239 Free PMC article.
-
Long-term cardiovascular, cerebrovascular, and thrombotic complications after SARS-CoV-2-Omicron infection: a retrospective cohort study.Clin Microbiol Infect. 2024 Oct;30(10):1319-1326. doi: 10.1016/j.cmi.2024.06.011. Epub 2024 Jun 20. Clin Microbiol Infect. 2024. PMID: 38908748
References
-
- Hoogenboom, W. S. et al. Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - A fifteen hospital observational study in the Bronx, New York. Haematologica106 (11), 3014–3016. 10.3324/haematol.2021.279222 (2021). - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous